natgillin/translations-raw huggingface dataset:
Considering all currently available data, the CHMP concluded that trimetazidine-containing medicines should be contraindicated in patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders. 
Ob upoštevanju vseh trenutno razpoložljivih podatkov je CHMP sklenil, da morajo biti zdravila, ki vsebujejo trimetazidin, kontraindicirana pri bolnikih s parkinsonovo boleznijo, simptomi parkinsonove bolezni, tremorji, sindromom nemirnih nog in drugimi povezanimi motnjami gibanja.
Overall, the CHMP concluded that after assessing the newly available data, the benefits continue to outweigh the risks in patients with angina pectoris but that treatment should be restricted to add-on to existing treatments in patients who are not adequately controlled by or intolerant to other medicines for angina pectoris. 
CHMP je po oceni na novo razpoložljivih podatkov zaključil, da koristi še naprej odtehtajo tveganja pri bolnikih z angino pektoris, vendar pa je treba zdravljenje omejiti na dodatno zdravljenje k že obstoječemu pri bolnikih, pri katerih angina pektoris ni pod ustreznim nadzorom ali ki drugih zdravil ne prenašajo.
• Considering all the currently available safety data the Committee concluded that trimetazidine should be contraindicated in patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders as well as in patients with severe renal impairment (creatinine clearance < 30ml/min). 
• Ob upoštevanju vseh trenutno razpoložljivih podatkov o varnosti je Odbor zaključil, da je treba trimetazidin kontraindicirati pri bolnikih s parkinsonovo boleznijo, simptomi parkinsonove bolezni, tremorji, sindromom nemirnih nog in drugimi povezanimi motnjami gibanja ter pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min).
The CHMP considers that the revised indication is in line with the scientific evidence available at present for trimetazidine as add-on therapy and it is supported by trials that became available after the initial authorisation and considered to be of sufficient methodological quality and by meta-analyses that have come to similar conclusions. 
Podpirajo jo tudi preskušanja, ki so postala razpoložljiva po prvotni odobritvi, za katera se meni, da so ustrezne metodološke kakovosti, ter metaanalize, pri katerih so prišli do podobnih zaključkov.
Considering all the currently available data the CHMP concluded that the trimetazidine should be contraindicated in patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders as well as in patients with severe renal impairment (creatinine clearance < 30ml/min). 
Ob upoštevanju vseh trenutno razpoložljivih podatkov je CHMP zaključil, da je treba trimetazidin kontraindicirati pri bolnikih s parkinsonovo boleznijo, simptomi parkinsonove bolezni, tremorji, sindromom nemirnih nog in drugimi povezanimi motnjami gibanja ter pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min).
No significant difference between groups could be found for the other secondary endpoints (total exercise duration, total workload and clinical endpoints). 
Za druge sekundarne opazovane dogodke (skupno trajanje vadbe, skupna obremenitev in klinične opazovane dogodke) ni bilo mogoče opaziti pomembnih razlik med skupinama.
was added to 50 mg atenolol (o.d.) for 8 weeks and produced a significant increase (+34.4s, p=0.03) in the time to 1-mm ST-segment depression in exercise tests, in a sub-group of patients (n=173), when compared to placebo, 12 hours after taking the drug. 
To je pri podskupini bolnikov (št. = 173) 12 ur po prejemu zdravila povzročilo znatno zvišanje (+34,4s; p = 0,03) časa do 1-mm znižanja spojnice ST v vadbenih testih v primerjavi s placebom.
Overall summary of the scientific evaluation of Kogenate Bayer and Helixate NexGen (see Annex A) 
Splošni povzetek znanstvenega vrednotenja zdravil Kogenate Bayer in Helixate NexGen (glejte Prilogo A)
Following the provisions under Article 20 of Regulation (EC) No 726/2004, the CHMP, having considered the PRAC recommendation dated 5 December 2013, is of the opinion that the marketing authorisations for Kogenate Bayer and Helixate NexGen should be varied as recommended by the PRAC (see Annex A). 
V skladu z določbami iz člena 20 Uredbe (ES) št. 726/2004 je CHMP po preučitvi priporočila odbora PRAC z dne 5. decembra 2013, podal mnenje, da je treba dovoljenja za promet z zdraviloma Kogenate Bayer in Helixate NexGen spremeniti v skladu s priporočili odbora PRAC (glejte Prilogo A).
• The PRAC considered the procedure under Article 20 of Regulation (EC) No 726/2004 for Kogenate Bayer and Helixate NexGen (see annexes A). 
• PRAC je obravnaval postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 za zdravili Kogenate Bayer in Helixate NexGen (glejte prilogi A);
The MAH also submitted data from four interventional clinical trials and six observational studies, which investigated the safety and efficacy of Kogenate Bayer/Helixate NexGen in haemophilia A patients, including studies 200021EU and 100074US in PUPs and minimally treated patients (MTPs). 
Imetnik dovoljenj za promet z zdraviloma je predložil tudi podatke iz štirih intervencijskih kliničnih preskušanj in šestih opazovalnih študij, v katerih so proučevali varnost in učinkovitost zdravil Kogenate Bayer in Helixate NexGen pri bolnikih s hemofilijo A, vključno s študijama 200021EU in
The reference Member State (RMS) is the United Kingdom and 12 concerned Member States (CMS) are involved: Austria, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, the Netherlands, Slovakia and Spain. 
Referenčna država članica je Združeno kraljestvo, zadevnih članic pa je 12: Avstrija, Češka republika, Estonija, Finska, Francija, Nemčija, Grčija, Italija, Latvija, Nizozemska, Slovaška in Španija.
The opinion was converted into a Decision by the European Commission on 12 August 2013. 
Mnenje je bilo dne 12. avgusta 2013 spremenjeno v sklep Evropske komisije.
The Committee appointed Mr J. Schefferlie as rapporteur and Ms H. Jukes as co-rapporteur. 
Odbor je za poročevalca imenoval g. J. Schefferlieja, za soporočevalko pa go. H. Jukes.
International non-proprietary name (INN): doxycycline hyclate 
Mednarodno nelastniško ime (INN): doksiciklinijev hiklat
The re-examination procedure started on 27 April 2013. 
Postopek ponovne presoje se je začel 27. aprila 2013.
The detailed grounds for the re-examination request were submitted by Eurovet Animal Health BV on 26 April 2013. 
Podrobne razloge za zahtevo za ponovno presojo je družba Eurovet Animal Health BV predložila 26. aprila 2013.
On 22 March 2013, Eurovet Animal Health BV notified the Agency of their intention to request a reexamination of the CVMP opinion of 7 March 2013. 
22. marca 2013 je družba Eurovet Animal Health BV agencijo obvestila, da namerava zaprositi za ponovno presojo mnenja odbora CVMP z dne 7. marca 2013.
During its meeting of 9-11 April 2013 the CVMP appointed Prof. C. Friis as the rapporteur and Dr M. Holzhauser-Alberti as the co-rapporteur for the re-examination procedure. 
Na zasedanju odbora CVMP, ki je potekalo od 9. do 11. aprila 2013, sta bila za poročevalca in soporočevalca v postopku ponovne presoje mnenja imenovana prof. C. Friis in dr. M. HolzhauserAlberti.
Potential serious risks were identified during the decentralised procedure by the Netherlands regarding the appropriate withdrawal period for chicken meat and offal. 
Med decentraliziranim postopkom je Nizozemska opozorila na morebitna resna tveganja v zvezi z ustrezno karenco za piščančje meso in organe.
It is indicated in chickens to reduce mortality, morbidity, and clinical signs and to reduce lesions due to Pasteurellosis caused by Pasteurella multocida or to reduce morbidity and lesions in respiratory infections caused by Ornithobacterium rhinotracheale (ORT). 
Zdravilo je indicirano za uporabo pri piščancih za zmanjšanje smrtnosti, obolevnosti in kliničnih znakov ter za zmanjšanje lezij, ki so posledica pastereloze, ki jo povzroča bakterija Pasteurella multocida, ali za zmanjšanje obolevnosti in lezij pri okužbah dihal, ki jih povzroča bakterija Ornithobacterium rhinotracheale (ORT).
On 30 October 2012, the reference Member State, the United Kingdom, notified the European Medicines Agency that the CMD(v) had failed to reach an agreement and referred the matter to the CVMP pursuant to Article 13(2) of Commission Regulation (EC) No. 1234/2008. 
Referenčna država članica, Združeno kraljestvo, je 30. oktobra 2012 Evropsko agencijo za zdravila obvestila, da CMD(v) ni dosegla soglasja o zdravilu in je v skladu s členom 13(2) Direktive Komisije (ES) št. 1234/2008 zadevo napotila na CVMP.
Day 60 of the CMD(v) procedure was on 18 October 2012, and since the Member States concerned failed to reach an agreement, the procedure was referred to the CVMP. 
Na šestdeseti dan postopka CMD(v) dne 18. oktobra 2012 zadevne države članice niso dosegle soglasja o zdravilu, zato je bil postopek napoten na odbor CVMP.
On day 90, these issues remained unsolved and therefore a referral under Article 13(1) of Commission Regulation (EC) No. 1234/2008 to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 20 August 2012. 
Ker ti pomisleki na 90. dan postopka še vedno niso bili rešeni, je bila zadeva 20. avgusta 2012 v skladu s členom 13(1) Direktive Komisije (ES) št. 1234/2008 napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek (zdravila za uporabo v veterinarski medicini) (CMD(v)).
There are two authorised dosages: 10 mg/kg bw for 4 consecutive days, for which the withdrawal period is 3 days, and 20 mg/kg bw for 4 consecutive days for which the withdrawal period is 12 days. 
Odobrena sta dva odmerka: 10 mg/kg telesne mase 4 dni zapored, pri čemer je karenca 3 dni, in 20 mg/kg telesne mase 4 dni zapored, pri čemer je karenca 12 dni.
Written explanations were provided by the marketing authorisation holder on 8 January 2013. 
Imetnik dovoljenja za promet z zdravilom je pisna pojasnila predložil 8. januarja 2013 ter 5. marca 2013 podal še ustna pojasnila.
The marketing authorisation holder, Eurovet Animal Health BV submitted an application for a type II variation to shorten the withdrawal period in chickens to 6 days for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names, which has been subject to a worksharing procedure by the CMDv according to Article 20 of Commission Regulation (EC) No 1234/2008. 
Imetnik dovoljenja za promet z zdravilom, družba Eurovet Animal Health BV, je predložil vlogo za spremembo tipa II za skrajšanje karence pri piščancih na 6 dni za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance in povezana imena, ki je bila predmet postopka za delitev dela s strani CMDv, v skladu s členom 20 Uredbe Komisije (ES) št. 1234/2008.
The CVMP concluded a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days. 
CVMP je zaključil, da je za odmerek 20 mg/kg telesne mase 4 dni zapored za piščance ustrezna 9-dnevna karenca.
The worksharing procedure (UK/V/xxxx/WS/006) involving Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) started on 6 January 2012. 
Postopek za delitev dela (UK/V/xxxx/WS/006) za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002) se je začel 6. januarja 2012.
Soludox 500 mg/g powder for use in drinking water for pigs and chickens contains doxycycline hyclate as active ingredient. 
Zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance vsebuje zdravilno učinkovino doksiciklinijev hiklat.
On 12 June 2013 the CVMP adopted a final opinion confirming the recommendation included in its opinion of 7 March 2013, that the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) can be granted and a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days. 
Odbor CVMP je 12. junija 2013 sprejel končno mnenje, s katerim je potrdil priporočilo, ki je bilo vključeno v mnenje Odbora z dne 7. marca 2013, da je mogoče odobriti spremembo dovoljenj za promet z zdravilom za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002) in da je za odmerek 20 mg/kg telesne mase 4 dni zapored za piščance ustrezna 9-dnevna karenca.
Based on the evaluation of the available data the CVMP adopted, on 7 March 2013, an opinion recommending the granting of the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002). 
Odbor CVMP je na podlagi ocene razpoložljivih podatkov 7. marca 2013 sprejel mnenje, da priporoča odobritev sprememb dovoljenj za promet z zdravilom za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002).
Opinion following an Article 131 referral for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names 
Mnenje v zvezi z napotitvijo v skladu s členom 130F za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance in povezana imena stran 2/2
The European Commission issued a decision on 29 January 2010. 
Evropska komisija je odločbo izdala dne 29. januarja 2010.
The CHMP opinion was confirmed after re-examination. 
Mnenje CHMP je bilo po ponovni presoji mnenja potrjeno.
When an antibiotic is produced using a natural source, as in this instance, there can be some differences in the composition of the finished product. 
Če se antibiotik izdeluje s pomočjo naravnega vira, kot v tem primeru, se lahko pojavijo razlike v sestavi končnega zdravila.
Re-examination 
Ponovna presoja
London, 22 October 2009 rev. Doc. 
London, 22. oktobra 2009 rev.
However, the Member States were not able to reach an agreement and the German Regulatory Agency referred the matter to the CHMP for arbitration on 8 October 2008. 
Vendar države članice niso mogle doseči soglasja, zato je nemška regulatorna agencija dne 8. oktobra 2008 zadevo napotila na CHMP.
This is a procedure when one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Ireland, Italy, Portugal, Spain and the United Kingdom). 
To je postopek, ko ena država članica („referenčna država članica“, v tem primeru Nemčija) presoja zdravilo z vidika odobritve dovoljenja za promet, ki bo veljavno v omenjeni državi ter v drugih državah članicah („zadevnih“ državah članicah, v tem primeru v Avstriji, na Irskem, v Italiji, na Portugalskem, v Španiji in v Združenem kraljestvu).
On 25 June 2009, the European Medicines Agency (EMEA) completed an arbitration procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Teicoplanin Hospira. 
Evropska agencija za zdravila (EMEA) je dne 25. junija 2009 končala postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije glede odobritve zdravila Teicoplanin Hospira.
After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal of the marketing authorisation on 22 October 2009. 
Po proučitvi podlage za to zahtevo je CHMP ponovno pregledal prvotno mnenje in dne 22. oktobra 2009 potrdil priporočilo za zavrnitev odobritve dovoljenja za promet z zdravilom.
Dr Barbara Van Zwieten-Boot 
dr. Karl Broich dr. Barbara Van Zwieten-Boot
It is use to treat patients with serious infections due to Grampositive bacteria. 
Uporablja se za zdravljenje bolnikov s hudimi okužbami z grampozitivnimi bakterijami.
Questions and answers on the referral for Teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin 
Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Teicoplanin Hospira prašek in vehikel za injiciranje z 200 ali 400 mg teikoplanina
Together, the cell wall and membrane form a barrier between the bacterial cell contents and the external environment. 
Celična stena in membrana skupaj tvorita pregrado med vsebino celične stene bakterij ter zunanjim okoljem.
Initial Assessment 
Prvotna presoja
Teicoplanin Hospira is a generic medicine based on a ‘reference medicine' authorised in Germany (Targocid 400 mg). 
Zdravilo Teicoplanin Hospira je generično zdravilo na podlagi „referenčnega zdravila“, ki je že odobreno v Nemčiji (Targocid 400 mg).
Gram-positive bacteria include bacteria such as staphylocci (Staphylococcus aureus), streptococci (Streptococcus pneumoniae), Listeria, Clostridium difficile. 
Grampozitivne bakterije so bakterije, kot so stafilokoki (Staphylococcus aureus), streptokoki (Streptococcus pneumoniae), Listeria, Clostridium difficile.
Medicines are bioequivalent when they produce the same levels of the active substance in the body. 
Zdravili sta biološko enakovredni, ko v telesu dosegata enake ravni zdravilne učinkovine.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and therefore the marketing authorisation should not be granted in the concerned Member States. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvenih razprav v odboru CHMP je ta zaključil, da koristi zdravila Teicoplanin Hospira ne odtehtajo z njim povezanih tveganj, zato se dovoljenje za promet z zdravilom v zadevnih državah članicah ne sme odobriti.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and the marketing authorisation cannot be granted in Germany and in other Member States of the EU (Austria, Ireland, Italy, Portugal, Spain and the United Kingdom). 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji EMEA je zaključil, da koristi zdravila Teicoplanin Hospira ne odtehtajo z njim povezanih tveganj, zato dovoljenja za promet z zdravilom ni mogoče odobriti v Nemčiji in drugih državah članicah EU (v Avstriji, na Irskem, v Italiji, na Portugalskem, v Španiji in v Združenem kraljestvu).
There were also concerns that the composition of the teicoplanin in Teicoplanin Hospira was different to that in Targocid, with a potential impact on the effectiveness of the medicine. 
Obstajali so tudi zadržki, da je bila sestava teikoplanina v zdravilu Teicoplanin Hospira drugačna kot v zdravilu Targocid, kar lahko vpliva na učinkovitost zdravila.
Dr Ian Hudson 
dr. Patrick Salmon dr. Ian Hudson
The grounds for the referral were concerns from Ireland and the United Kingdom that Teicoplanin Hospira had not been shown to be bioequivalent to Targocid. 
Razlogi za napotitev so bili zadržki Irske in Združenega kraljestva, da za zdravilo Teicoplanin Hospira ni bila dokazana biološka enakovrednost zdravilu Targocid.
The company that makes Teicoplanin Hospira, Hospira UK Limited, requested a re-examination of the opinion. 
Izdelovalec zdravila Teicoplanin Hospira, družba Hospira UK Limited, je zahteval ponovno presojo mnenja.
Why was Teicoplanin Hospira reviewed? 
Zakaj je bilo zdravilo Teicoplanin Hospira pregledano?
Company responses provided on: 23 January 2009 and 27 May 2009 
23. januar 2009 in 27. maj 2009 3. september 2009
Teicoplanin Hospira can only be used in patients who cannot receive penicillin or cephalosporins antibiotics, or if these antibiotics have stopped working or the infection is due to a Staphylococcus that is resistant to other antibiotics. 
Zdravilo Teicoplanin Hospira se lahko uporablja le pri bolnikih, ki ne smejo prejeti penicilinskih ali cefalosporinskih antibiotikov, ali kadar ti antibiotiki ne učinkujejo več ali ko okužbo povzroči bakterija Staphylococcus, ki je odporna proti tem antibiotikom.
These bacteria can cause skin infections, lung infections, joint and bone infections, heart infections or infections of the urinary tract (structures that carry urine). 
Te bakterije lahko povzročijo okužbe kože, pljuč, sklepov in kosti, srčne mišice ali sečil (struktur za odvajanje urina).
It works by stopping the bacteria making their cell walls and by disrupting their cell membranes. 
Deluje tako, da v bakterijah prekine izdelavo celične stene in poruši celično membrano.
Teicoplanin Hospira can also be used to prevent infections in patients undergoing surgery of the bones, joint or blood vessels. 
Zdravilo Teicoplanin Hospira se lahko uporablja tudi za preprečevanje okužb pri bolnikih s kirurškim posegom na kosteh, sklepih ali ožilju.
Hospira UK Limited submitted Teicoplanin Hospira to the German Regulatory Agency for a decentralised procedure. 
Družba Hospira UK Limited je nemški regulatorni agenciji predložila vlogo za pridobitev dovoljenja za promet z zdravilom Teicoplanin Hospira po decentraliziranem postopku.
By disrupting this barrier, teicoplanin kills the bacteria that are causing the infection. 
Ko teikoplanin prekine to pregrado, uniči bakterije, ki povzročajo okužbo.
Teicoplanin Hospira is an antibiotic. 
Zdravilo Teicoplanin Hospira je antibiotik.
What is Teicoplanin Hospira? 
Kaj je zdravilo Teicoplanin Hospira?
This is because teicoplanin in Teicoplanin Hospira is made by fermentation, using a bacterium called Actinoplanes to produce the antibiotic. 
To je posledica izdelave teikoplanina v zdravilu Teicoplanin Hospira s postopkom fermentacije in bakterijo Actinoplanes, ki tvori antibiotik.
The active substance in Teicoplanin Hospira, teicoplanin, is an antibiotic that belongs to the group ‘glycopeptides'. 
Zdravilna učinkovina zdravila Teicoplanin Hospira, teikoplanin, je antibiotik iz skupine „glikopeptidov“.
Referral start date: 
Odgovori družbe, poslani dne:
Adopted at the 14-17 January 2019 PRAC 
Sprejeto na seji odbora PRAC, 14.-17. januarja 2019
Gabapentin - Dysphagia (EPITT no 19296) 
Gabapentin - disfagija (EPITT št. 19296)
The risk of interference is higher in children and patients with renal impairment and increases with higher doses. 
Tveganje za vpliv je večje pri otrocih in bolnikih z ledvično okvaro ter se povečuje z večjimi odmerki.
For medicinal products for oral use containing ≥150 microgram biotin per dose unit and medicinal products for parenteral use containing ≥60 microgram biotin per dose unit 
Za zdravila za peroralno uporabo, ki vsebujejo ≥ 150 mikrogramov biotina na enoto odmerka, in zdravila za parenteralno uporabo, ki vsebujejo ≥ 60 mikrogramov biotina na enoto odmerka
Interference with clinical laboratory tests 
Vpliv na klinične laboratorijske preiskave
[Product name] contains <quantity> biotin per <dose unit>. 
Zdravilo [ime zdravila] vsebuje <količina> biotina na <enota odmerka>.
Please inform your doctor or the laboratory personnel, if you are taking such products. 
Obvestite zdravnika ali laboratorijsko osebje, če jemljete tovrstne izdelke.
You should also be aware that other products that you may take, such as multivitamins or supplements for hair, skin, and nails could also contain biotin and affect the results of laboratory tests. 
Poleg tega upoštevajte, da lahko tudi drugi izdelki, ki jih morda jemljete, na primer multivitamini ali prehranska dopolnila za lase, kožo in nohte, vsebujejo biotin in vplivajo na rezultate laboratorijskih preiskav.